Related Experiment Videos
Short-term morbidity from CT-planned transperineal I-125 prostate implants
V E Arterbery1, K Wallner, J Roy
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
Summary
Transperineal CT-guided Iodine-125 (I-125) prostate implantation causes temporary urinary issues but shows promising short-term tumor response and high potency preservation.
Area of Science:
- Urology
- Radiation Oncology
- Medical Physics
Background:
- Prostate cancer treatment requires effective methods with manageable side effects.
- Minimally invasive techniques like brachytherapy are increasingly explored.
Purpose of the Study:
- To evaluate short-term morbidity and tumor response after transperineal CT-guided Iodine-125 (I-125) prostate implantation.
- To assess the safety and efficacy of this brachytherapy technique.
Main Methods:
- Twenty-one patients underwent CT-guided transperineal I-125 prostate implantation.
- An average of 75 I-125 seeds (0.62 mCi/seed) were used.
- Patient symptoms were meticulously documented through interviews.
Main Results:
- Most patients experienced temporary urinary symptoms (dysuria, nocturia, frequency) for 2-24 weeks.
- Urinary symptoms resolved within 4-6 months post-implantation.
- A 94% one-year actuarial potency rate was observed in previously potent patients.
- 82% of Stage B tumors showed complete regression by 6 months.
- 76% of patients with Stage A or B tumors and elevated PSA normalized levels within 6 months.
Conclusions:
- CT-guided transperineal I-125 prostate implants result in moderate, transient urinary and rectal morbidity.
- The short-term tumor response and potency preservation are encouraging outcomes.